Europe Non-Small Cell Lung Cancer Treatments Market Opportunities, 2010 - 2020

Date: February 4, 2015
Pages: 122
Price:
US$ 3,000.00
License [?]:
Publisher: Pharmaion Consultants
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: E611A04AE55EN
Leaflet:

Download PDF Leaflet

Europe Non-Small Cell Lung Cancer Treatments Market Opportunities, 2010 - 2020
In Europe, lung cancer accounts for around 20% of the total deaths due to cancer. With a 5-year survival rate of 11.2% for men and 13.9% for women in 2014, lung cancer is the leading cause of cancer related deaths in Europe. Majority of the lung cancer patients in Europe were found to be suffering from Non-Small Cell Lung Cancer (NSCLC) in 2014, and the trend is anticipated to continue through 2020. Hence, with increasing prevalence of NSCLC among European citizens, demand for NSCLC treatment is forecast to grow at a robust pace over the next five years.

“Europe Non-Small Cell Lung Cancer Treatments Market Opportunities, 2010 - 2020” report studies the market size and share of various segments and sub-segments of the non- small cell lung cancer treatments market in the Europe during the period 2010 - 2020. In the study, the market has been categorized into four broader segments that include Chemotherapy, Surgery, Radiotherapy & Target Therapy.

The market dynamics section of the report elaborates the factors that are driving the market as well as the challenges inhibiting growth. The research study also includes insights of the key market trends, a detailed analysis of the changing competitive landscape, and revenue forecasts for each segment and sub-segment.

All this information is provided to assist the established market players and new entrants in taking their strategic decisions, thereby aiding them in strengthening their market position in a highly competitive non-small cell lung cancer treatments market in Europe.

“Europe Non-Small Cell Lung Cancer Treatments Market Opportunities, 2010 - 2020” report elaborates the following aspects of non-small cell lung cancer treatments market in Europe:
  • Europe Non-Small Cell Lung Cancer Treatments Market Size, Share & Forecast
  • Segmental Analysis – By Target Disease, By Type, By Region, By Company
  • Policy & Regulatory Landscape
  • Changing Market Trends & Emerging Opportunities
  • Competitive Landscape & Strategic Recommendations
Why You Should Buy This Report?
  • To identify the on-going trends and anticipated growth in the next five years
  • To gain competitive knowledge of leading market players
  • To avail 10% customization in the report without any extra charges and get the research data or trends added in the report as per the buyer’s specific needs
Key Questions This Study Will Answer
  • What would be the segmental and regional growth trends in the Europe non-small cell lung cancer treatments market in the coming years?
  • What are the most important growth drivers and opportunities in the market?
  • Which therapy is preferred the most?
  • What strategies should market competitors employ to gain share in mature segments of the Europe non-small cell lung cancer treatments market?
  • What are the competitor profiles in this market and how do they compete for market share?
Report Methodology

The information contained in this report is based upon both primary and secondary sources. Primary research included interviews with NSCLC drug manufacturers, healthcare providers and industry experts. Secondary research included an exhaustive search of relevant publications like company annual reports, financial reports and proprietary databases
1. NON-SMALL CELL LUNG CANCER TREATMENT OVERVIEW

2. RESEARCH METHODOLOGY

3. ANALYST VIEW

4. GLOBAL NON-SMALL CELL LUNG CANCER TREATMENT MARKET OVERVIEW

5. EUROPE LUNG CANCER EPIDEMIOLOGY

6. EUROPE NON-SMALL CELL LUNG CANCER TREATMENT MARKET OVERVIEW

7. EUROPE NON-SMALL CELL LUNG CANCER TREATMENT MARKET OUTLOOK

7.1. Market Size & Forecast
  7.1.1. By Value
7.2. Market Share & Forecast
  7.2.1. By Targeted Disease (Squamous & Non-squamous)
  7.2.2. By Type (Surgery, Radiotherapy, Chemotherapy & Target Therapy)
  7.2.3. By Region (Germany, UK, Italy, France, Spain & RoE)
  7.2.4. By Company

8. EUROPE NON-SMALL CELL LUNG CANCER TREATMENT REGIONAL MARKET OUTLOOK

8.1. Germany Non-Small Cell Lung Cancer Treatment Market Analysis
  8.1.1. Market Size & Forecast
    8.1.1.1. By Value
  8.1.2. Market Share & Forecast
    8.1.2.1. By Type (Surgery, Radiotherapy, Chemotherapy & Target Therapy)
8.2. Italy Non-Small Cell Lung Cancer Treatment Market Analysis
  8.2.1. Market Size & Forecast
    8.2.1.1. By Value
  8.2.2. Market Share & Forecast
    8.2.2.1. By Type (Surgery, Radiotherapy, Chemotherapy & Target Therapy)
8.3. Spain Non-Small Cell Lung Cancer Treatment Market Analysis
  8.3.1. Market Size & Forecast
    8.3.1.1. By Value
  8.3.2. Market Share & Forecast
    8.3.2.1. By Type (Surgery, Radiotherapy, Chemotherapy & Target Therapy)
8.4. UK Non-Small Cell Lung Cancer Treatment Market Analysis
  8.4.1. Market Size & Forecast
    8.4.1.1. By Value
  8.4.2. Market Share & Forecast
    8.4.2.1. By Type (Surgery, Radiotherapy, Chemotherapy & Target Therapy)
8.5. France Non-Small Cell Lung Cancer Treatment Market Analysis
  8.5.1. Market Size & Forecast
    8.5.1.1. By Value
  8.5.2. Market Share & Forecast
    8.5.2.1. By Type (Surgery, Radiotherapy, Chemotherapy & Target Therapy)

9. EUROPE NON-SMALL CELL LUNG CANCER TREATMENT SEGMENTAL MARKET OUTLOOK

9.1. Europe NSCLC Chemotherapy Market Outlook
  9.1.1. Market Size & Forecast
    9.1.1.1. By Value
  9.1.2. Market Share & Forecast
    9.1.2.1. By Type (First Line Therapy, Maintenance Therapy, Second Line Therapy, Third Line Therapy & Adjuvant Therapy)
9.2. Europe NSCLC Surgery Market Outlook
  9.2.1. Market Size & Forecast
    9.2.1.1. By Value
  9.2.2. Market Share & Forecast
    9.2.2.1. By Type (Lobectomy, Sleeve Resection, Segmentectomy, Pneumonectomy & Others)
9.3. Europe NSCLC Radiotherapy Market Outlook
  9.3.1. Market Size & Forecast
    9.3.1.1. By Value
  9.3.2. Market Share & Forecast
    9.3.2.1. By Type (External Beam Radiation therapy, Internal Beam Radiation Therapy & Systemic Radiation Therapy)
9.4. Europe NSCLC Target Therapy Market Outlook
  9.4.1. Market Size & Forecast
    9.4.1.1. By Value
  9.4.2. Market Share & Forecast
    9.4.2.1. By Type (Monoclonal Antibodies (MABs) + Gene Therapy & Others)

10. MARKET DYNAMICS

10.1. Drivers
10.2. Challenges

11. MARKET TRENDS AND DEVELOPMENTS

11.1. Development of New Therapeutics in Immunotherapy
11.2. Video Assisted Thoracic Surgery
11.3. Photodynamic Therapy (PDT)
11.4. Laser Therapy
11.5. Biomarkers

12. POLICY AND REGULATORY LANDSCAPE

13. EUROPE NSCLC PRODUCT ROADMAP

14. COMPETITIVE LANDSCAPE

14.1. Company Profiles
  14.1.1. Roche Holding AG
  14.1.2. Eli Lilly and Company Limited
  14.1.3. Boehringer Ingelheim GmbH
  14.1.4. Pfizer AG
  14.1.5. AstraZeneca
  14.1.6. Celgene International Sarl
  14.1.7. Bristol-Myers Squibb
  14.1.8. Merck Sharp & Dohme Limited
  14.1.9. Novartis AG
  14.1.10. Teva Pharmachemie

15. STRATEGIC RECOMMENDATIONS

LIST OF TABLES

Table 1: Non-Small Cell Lung Cancer Treatment Algorithm, By Stage
Table 2: Europe Lung Cancer Incidence and Prevalence Rate, By Country, 2012 (%)
Table 3: Europe NSCLC Patient Population Undergoing Drug Therapy, 2012
Table 4: Average Lifetime Cost Per Patient of NSCLC Treatment in Europe, By Target Disease, 2014 (USD)
Table 5: Europe Average Lifetime NSCLC Treatment Cost Per Patient, By Country, 2014 (USD)
Table 6: Europe Prevalence of Tobacco Use, By Age Group, By Country, 2015 & 2020E (%)
Table 7: Germany Proportion of Non-Small Cell Lung Cancer Patients Undergoing Different Treatment Therapies, By Stage (%)
Table 8: Proportion of NSCLC Patients Diagnosed in England, By Stage, 2014 (%)
Table 9: Proportion of Patients with Recurrent Lung Cancer in England, By Stage, 2014
Table 10: Individual NSCLC Patient Treatment Cost (USD) in England, By Therapy Type, 2014
Table 11: Europe Non-Small Cell Lung Cancer Chemotherapeutic Agents
Table 12: Europe Marketed Partial List of Target Therapy Drug
Table 13: List of Therapeutic Vaccines under Clinical Trial in European Union in 2015
Table 14: List of Immunotherapy Drug in European Union in 2015
Table 15: List of National Regulatory Authority in Top 5 European Union Countries for Authorization of Drugs
Table 16: List of Pipeline Drugs under Clinical Trial Phase 3 for NSCLC in European Union, 2015
Table 17: List of Marketed Targeted Therapy Drugs for NSCLC in European Union, 2015

LIST OF FIGURES

Figure 1: Europe Lung Cancer Incidences, By Gender, 2012 & 2015E
Figure 2: Europe Number of Deaths due to Lung Cancer, By Gender, 2012 & 2015E
Figure 3: Europe Lung Cancer Prevalence, By Country, 2012
Figure 4: Europe Non-Small Cell Lung Cancer Treatment Market Size, By Value, 2010-2020F (USD Million)
Figure 5: Europe Non-Small Cell Lung Cancer Treatment Market, By Target Disease, By Value, 2010-2020F
Figure 6: Europe Non-Small Cell Lung Cancer Treatment Market Share, By Type, By Value, 2010-2020F
Figure 7: Europe Non-Small Cell Lung Cancer Treatment Market Share, By Region, By Value, 2010-2020F
Figure 8: Europe Non-Small Cell Lung Cancer Treatment Market Share, By Company, By Value, 2010-2020F
Figure 9: Germany Non-Small Cell Lung Cancer Treatment Market Size, By Value, 2010-2020F (USD Million)
Figure 10: Germany Non-Small Cell Lung Cancer Treatment Market Share, By Type, By Value, 2010-2020F
Figure 11: France Non-Small Cell Lung Cancer Treatment Market Size, By Value, 2010-2020F (USD Million)
Figure 12: France Non-Small Cell Lung Cancer Treatment Market Share, By Type, By Value, 2010-2020F
Figure 13: Spain Non-Small Cell Lung Cancer Treatment Market Size, By Value, 2010-2020F (USD Million)
Figure 14: Spain Non-Small Cell Lung Cancer Treatment Market Share, By Type, By Value, 2010-2020F
Figure 15: Italy Non-Small Cell Lung Cancer Treatment Market Size, By Value, 2010-2020F (USD Million)
Figure 16: Italy Non-Small Cell Lung Cancer Treatment Market Share, By Type, By Value, 2010-2020F
Figure 17: United Kingdom Non-Small Cell Lung Cancer Treatment Market Size, By Value, 2010-2020F (USD Million)
Figure 18: United Kingdom Non-Small Cell Lung Cancer Treatment Market Share, By Type, By Value, 2010-2020F
Figure 19: Europe Non-Small Cell Lung Cancer Chemotherapy Market Size, By Value, 2010-2020
Figure 20: Europe Non-Small Cell Lung Cancer Chemotherapy Market Share, By Type, By Value, 2010-2020
Figure 21: Europe Non-Small Cell Lung Cancer Surgery Market Size, By Value, 2010-2020
Figure 22: Europe Non-Small Cell Lung Cancer Surgery Market Share, By Type, By Value, 2010-2020
Figure 23: Europe Non-Small Cell Lung Cancer Radiotherapy Market Size, By Value (USD Million), 2010-2020
Figure 24: Europe Non-Small Cell Lung Cancer Radiotherapy Market Share, By Type, By Value, 2010-2020
Figure 25: Europe Non-Small Cell Lung Cancer Target Therapy Market Size, By Value, 2010-2020 (USD Million)
Figure 26: Europe Non-Small Cell Lung Cancer Target Therapy Market Share, By Type, By Value, 2014 & 2020F

COMPANIES MENTIONED

1. Roche Holding AG
2. Eli Lilly and Company Limited
3. Boehringer Ingelheim GmbH
4. Pfizer AG
5. AstraZeneca
6. Celgene International Sarl
7. Bristol-Myers Squibb
8. Merck Sharp & Dohme Limited
9. Novartis AG
10. Teva Pharmachemie
Skip to top


Ask Your Question

Europe Non-Small Cell Lung Cancer Treatments Market Opportunities, 2010 - 2020
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: